Enrichment of presenilin 1 peptides in the membranes of neuronal vesicles: Implications for Alzheimer's disease

被引:0
|
作者
Efthimiopoulos, S [1 ]
Georgakopoulos, A [1 ]
Floor, E [1 ]
Shioi, J [1 ]
Cui, W [1 ]
Wisniewski, T [1 ]
Robakis, NK [1 ]
机构
[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
来源
ALZHEIMER'S DISEASE AND RELATED DISORDERS: ETIOLOGY, PATHOGENESIS AND THERAPEUTICS | 1999年
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) is caused by heterogeneous genetic and probably environmental factors. Although the etiology of the disease is still not clear, several lines of evidence indicate that the integrity and number of cellular organelles that sustain neuronal vesicular axoplasmic transport, including ER, Golgi, endosomes and LDCVs are compromised in AD. These observations suggest that those factors that compromise neuronal vesicular transport may also be causally involved in the development of AD. This hypothesis, while it does not disregard the pathological significance and consequences of NFTs and NPs, emphasizes the need to search for abnormalities in neuronal protein transport upstream of the formation of NFTs and NPs. Presenilin 1 (PS1) is an integral membrane protein of unknown function. Most of this protein is cleaved post-translationally to yield an N-terminal fragment and a C-terminal fragment. Many PS1 mutants have been linked to the development of FAD. We obtained evidence that PS1 proteolytic fragments are enriched in LDCVs, CGs, and SDCCV preparations, suggesting that this protein is expressed in these vesicles and may play a role in vesicular function. These observations raise the possibility that PS1 FAD mutations interfere with the vesicular function of the PS1 fragments and cause AD, according to a model where multiple mutations of a protein induce the same disease phenotype by affecting multiple properties of the protein.
引用
收藏
页码:201 / 212
页数:12
相关论文
共 50 条
  • [41] A presenilin-1 mutation in a Japanese family with Alzheimer's disease
    Aoki, M
    Abe, K
    Tsuda, T
    Morita, M
    Itoyama, Y
    Oda, N
    Kanai, M
    Watanabe, M
    Shoji, M
    Ikeda, M
    NEUROLOGY, 1997, 48 (03) : 1096 - 1096
  • [43] Development of Alzheimer's disease through presenilin
    Takashima, A
    SEIKAGAKU, 1999, 71 (11): : 1331 - 1336
  • [44] Function and dysfunction of presenilin in Alzheimer’s disease
    Jie Shen
    Molecular Neurodegeneration, 8 (Suppl 1)
  • [45] Pick bodies in a family with presenilin-1 Alzheimer's disease
    Halliday, GM
    Song, YJC
    Lepar, G
    Brooks, WS
    Kwok, JB
    Kersaitis, C
    Gregory, G
    Shepherd, CE
    Rahimi, F
    Schofield, PR
    Kril, JJ
    ANNALS OF NEUROLOGY, 2005, 57 (01) : 139 - 143
  • [46] The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease
    Hamilton, Kirsty
    Harvey, Jenni
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 14
  • [47] Alzheimer's disease - Molecular consequences of presenilin-1 mutation
    Gandy, S
    Naslund, J
    Nordstedt, C
    NATURE, 2001, 411 (6838) : 654 - 655
  • [48] Presenilin-1 polymorphism in Alzheimer's disease and vascular dementia
    Matsushita, S
    Arai, H
    Muramatsu, T
    Makimoto, K
    Nakagawa, T
    Sasaki, H
    Higuchi, S
    EXPERIMENTAL NEUROLOGY, 1997, 146 (02) : 567 - 569
  • [49] Presenilin interactions and Alzheimer's disease - Response
    Tanzi, RE
    Finch, CE
    SCIENCE, 1998, 279 (5350) : 464 - 465
  • [50] Presenilin 1 modifies lipid raft composition of neuronal membranes
    Eckert, Gunter P.
    Mueller, Walter E.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 382 (04) : 673 - 677